Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy.

Literature DB >> 27476874

Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy.

Jochen Hammes¹, Gérard N Bischof^1,2, Kathrin Giehl¹, Jennifer Faber^3,4, Alexander Drzezga^1,4, Thomas Klockgether^3,4, Thilo van Eimeren^1,2,4.

Abstract

Entities: Chemical Disease Species

Keywords: PSP; Richardson syndrome; atypical parkinsonism; tau PET

Mesh：

Substances：

Year: 2016 PMID： 27476874 DOI： 10.1002/mds.26727

Source DB: PubMed Journal: Mov Disord ISSN： 0885-3185 Impact factor: 10.338

Keyword Cloud
Cited

× No keyword cloud information.

28 in total

Review 1. Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors: Keith A Josephs
Journal: Mayo Clin Proc Date: 2017-08 Impact factor: 7.616

2. Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology.

Authors: Shunsuke Koga; Maiko Ono; Naruhiko Sahara; Makoto Higuchi; Dennis W Dickson
Journal: Mov Disord Date: 2017-04-25 Impact factor: 10.338

3. [The importance of molecular imaging (PET) in the diagnostics of dementia].

Authors: M Tscheuschler; M Gebest; F Jessen; A Drzezga
Journal: Nervenarzt Date: 2018-07 Impact factor: 1.214

4. [Tauopathies : From molecule to therapy].

Authors: G G Kovacs; G Respondek; T van Eimeren; E Höller; J Levin; U Müller; S Schwarz; T W Rösler; K Schweyer; G U Höglinger
Journal: Nervenarzt Date: 2018-10 Impact factor: 1.214

5. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.

Authors: Marta Marquié; Marc D Normandin; Avery C Meltzer; Michael Siao Tick Chong; Nicolas V Andrea; Alejandro Antón-Fernández; William E Klunk; Chester A Mathis; Milos D Ikonomovic; Manik Debnath; Elizabeth A Bien; Charles R Vanderburg; Isabel Costantino; Sara Makaretz; Sarah L DeVos; Derek H Oakley; Stephen N Gomperts; John H Growdon; Kimiko Domoto-Reilly; Diane Lucente; Bradford C Dickerson; Matthew P Frosch; Bradley T Hyman; Keith A Johnson; Teresa Gómez-Isla
Journal: Ann Neurol Date: 2017-01 Impact factor: 10.422

6. [¹⁸ F]AV-1451 tau positron emission tomography in progressive supranuclear palsy.

Authors: Jennifer L Whitwell; Val J Lowe; Nirubol Tosakulwong; Stephen D Weigand; Matthew L Senjem; Christopher G Schwarz; Anthony J Spychalla; Ronald C Petersen; Clifford R Jack; Keith A Josephs
Journal: Mov Disord Date: 2016-10-27 Impact factor: 10.338

Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy.

Review 1. Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

2. Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to α-synuclein pathology.

3. [The importance of molecular imaging (PET) in the diagnostics of dementia].

4. [Tauopathies : From molecule to therapy].

5. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies.

6. [¹⁸ F]AV-1451 tau positron emission tomography in progressive supranuclear palsy.

Review 7. New Imaging Markers for Movement Disorders.

Review 8. The Role of Tau Imaging in Parkinsonian Disorders.

9. Multimodal correlation of dynamic [¹⁸F]-AV-1451 perfusion PET and neuronal hypometabolism in [¹⁸F]-FDG PET.

10. Tau Imaging in Parkinsonism: What Have We Learned So Far?